Patient Home Monitoring (PHM) Announces April 2012 Monthly Financial Metrics and Growth Figures, the Launch of Its National D...

Patient Home Monitoring Corp. (TSX VENTURE:PHM), a company focused on in-home
cardiology healthcare services, today announced monthly revenue figures as well
as growth in terms of meters shipped for the month of April 2012. 


As it embarks on a clinic roll-up strategy, PHM continues to improve its clinic
operations. As part of this improvement, phm launched its national dosing
support center for clinicians prescribing anti-coagulants for patients in the
united states.


Launch of national dosing support center 

PHM is proud to announce it has launched a national dosing support center headed
by a prominent clinician. The center, the first of its kind in the united
states, is staffed with highly qualified registered nurses with extensive
experience in dosing patients on anti-coagulants under standard protocols. The
center is the next step required for a rapid and scaled expansion into
additional management of clinic operations. The center is a novel and cost
effect approach to managing thousands of patients in a high quality, uniform
fashion. PHM believes that building a repository for patients across the country
on anti-coagulants will create tremendous value. 


As PHM manages clinics, all dosing will be supported from this efficient
centralized center.


Monthly growth 

Each month, PHM has grown by adding patients to their long-term annuity stream
business. To better communicate this trend and its impact on the business, two
figures will be reported:


1. Monthly Growth. PHM generates a recurring revenue stream from enrolled
testers by recording a weekly INR value and transmitting the information to the
patient's healthcare provider. 




--  In April of 2012, PHM recorded 8,245 INR tests. 

----------------------------------------------------------------------------
Month (Quarter)          INR Tests                                       Sum
----------------------------------------------------------------------------
1st Quarter                                19,434 total tests recorded in Q1
----------------------------------------------------------------------------
2nd Quarter                                23,581 total tests recorded in Q2
----------------------------------------------------------------------------
April (Q3)                   8,245     51,260 total tests recorded in FY2012
----------------------------------------------------------------------------



2. New Meters Shipped. Once enrolled, PHM ships a meter to a patient. This meter
has an expected 5-year economic life. With this meter investment, PHM generates
recurring revenue by providing weekly monitoring services to the patient. 


Understanding how many meters were shipped to newly enrolled patients each month
is relevant for analyzing growth because shipment of a meter is a prerequisite
to performing INR (1) tests eligible for reimbursement (2). 


PHM shipped 104 meters in April 2012, the first month of the third quarter
fiscal 2012. 




----------------------------------------------------------------------------
                            Meters  Total Meters Shipped (running total) for
Month (Quarter)            Shipped           the Quarter; Total for the Year
----------------------------------------------------------------------------
1st Quarter                                   501 total meters shipped in Q1
----------------------------------------------------------------------------
2nd Quarter                                   504 total meters shipped in Q2
----------------------------------------------------------------------------
April (Q3)                     104        1,109 new meters shipped in FY2012
----------------------------------------------------------------------------



"As announced last month, we continue to focus on improving our clinical
operations to enable rapid and full scale management of clinics," said Dr. Jaime
Gerber, PHM's CEO. "We continue to believe in the power of clinic management.
Our two current clinic operations have confirmed this demand. In fact, we still
have a backlog of patients who have expressed an interest in our service from
these clinics. " 


"We are committed to build a proper platform to meet this patient demand over
the long run," continued Dr. Gerber. "We see several clinic opportunities with
thousands of patients. In order to provide a quality partnership to both
patients and referring doctors, we are going to take some time to ensure our
operations are solid. Once we have achieved this goal, we will begin enrolling
aggressively again. There are still millions of patients in need of our service
and I see demand only increasing."


About PHM 

PHM is a healthcare services company focused on providing home-based monitoring
services and supplies for cardiology patients. PHM's entry-point service
monitors patients on blood thinner medications such as Coumadin(R) or warfarin.
Medicare recently expanded reimbursement for this in-home service. PHM has a
unique value proposition to cardiology groups that manage patients on blood
thinners, focusing on systemization to enroll patients in PST. This unique,
systemized approach creates an opportunity for physician groups to operate more
efficiently, increasing revenue to their clinic while providing a higher
standard of care for patients. PHM plans to lever its position as a value-added
service provider to expand into other home-based services for these patients and
their referring physicians. 


Information in this news release that is not current or historical factual
information may constitute forward-looking information within the meaning of
securities laws. Implicit in this information, particularly in respect of the
future outlook of PHM and anticipated events or results, are assumptions based
on beliefs of PHM's senior management as well as information currently available
to it. While these assumptions were considered reasonable by PHM at the time of
preparation, they may prove to be incorrect. Readers are cautioned that actual
results are subject to a number of risks and uncertainties, including the
availability of funds and resources to pursue operations, decline of
reimbursement rates, changes in US healthcare laws, coverage or budgets,
dependence on few payors, possible new drug discoveries, a novel business model,
dependence on key suppliers, granting of permits and licenses in a highly
regulated business, competition, low profit market segments as well as general
economic, market and business conditions, and could differ materially from what
is currently expected. 


(1) International normalized ratio ("INR") tests are used as measures of current
and future sales performance. Please refer to the "Non-GAAP Measures" section of
PHM's MD&A for further discussion on these operational measures 


(2) Management does not mean to suggest or imply that shipment of meters is
equivalent to revenue. Meter shipment is a prerequisite, but not a guarantee, of
revenue. Management does not propose meter shipments as a non-GAAP financial
measurement, because there is no simple reconciliation between meter shipment
and GAAP revenue.